Question 1

What is Anubis BioConsulting?

Accepted Answer

We exist because too many life sciences investment decisions are made on narrative rather than evidence, and too many great science companies stall at the capital interface. We're not a generalist strategy firm with a science vertical; we're scientists who learned the capital side. We help science-driven companies raise capital, navigate regulation, and build products, and we help investors evaluate life sciences opportunities with technical rigor.

Question 2

Who do you typically work with?

Accepted Answer

Two groups: (1) science-driven companies — startups, founders, and small biotech, medtech, and pharma firms; and (2) private equity firms, VCs, and investors assessing life sciences deals.

Question 3

Who actually does the work?

Accepted Answer

Engagements are led by our core team and supported by a trusted network of specialists: financial advisors, science and technology experts, scientific writers, medtech and IT experts, and regulatory advisors, among others. We assemble the right mix for each project rather than forcing a one-size-fits-all team.

Question 4

What areas do you cover?

Accepted Answer

Our team's background spans immunology, medtech, neurosciences, and oncology. Through past engagements, we've also worked across bioinformatics, computational biology, diagnostics, food technology, environmental sciences, and ESG — and we tap our expert network to extend into adjacent areas as needed.

Question 5

Where are you based, and do you work internationally?

Accepted Answer

We operate across the US and EU and support clients globally.

Question 6

What services do you offer to biotech, medtech, and pharma startups?

Accepted Answer

Strategy and roadmapping, clinical and regulatory pathway design, FDA/EMA submissions, grant writing, IP strategy, and investor-ready pitch decks.

Question 7

Can you help us write grant applications?

Accepted Answer

Yes. We develop grant applications, including SBIR/STTR, R21, R01, and DOD submissions, among others. We've worked on grant applications across bioinformatics, oncology, biology, and environmental sciences.

Question 8

Can you help us prepare a pitch deck for investors?

Accepted Answer

Absolutely. We build investor-ready pitch decks grounded in scientific rigor and aligned to what life sciences investors actually want to see. Recent work includes pitch decks and fundraising support across environmental science, bioinformatics, diagnostics, and oncology.

Question 9

What does your due diligence service include?

Accepted Answer

Competitive intelligence, market analysis, IP review, regulatory navigation, technology assessment, and identification of KOLs and domain specialists. We've delivered due diligence across sectors ranging from oncology to textile recycling, along with ESG and legal case reports focused on health and environment.

Question 10

Why use Anubis BioConsulting instead of a generalist firm?

Accepted Answer

We bring strong scientific and technological understanding to the investment process, so decisions are based on evidence, not just narrative.

Question 11

Do you have access to subject-matter experts and KOLs?

Accepted Answer

Yes. We maintain a trusted network of Key Opinion Leaders (KOLs) and domain specialists we can mobilize per engagement.

Question 12

How do engagements start, and how long do they take?

Accepted Answer

With a free intro chat: email info@anubisbc.com or fill out our contact form. Project length varies, from short-term due diligence sprints to multi-month regulatory and fundraising engagements; we scope timelines during the initial conversation.

Question 13

How are your services priced?

Accepted Answer

Pricing depends on scope, complexity, and duration. We also consider alternative payment structures on a case-by-case basis, and provide tailored proposals after the initial consultation.

Question 14

Do you sign NDAs?

Accepted Answer

Yes: confidentiality is standard practice on every engagement. We use NDAs tailored to each project and reviewed by our legal team to ensure balanced, appropriate terms for both sides.

Blog

Click on the image to open

First Proton Therapy Clinical Trial for Cancer

Remembering Dolly Parton

Rethinking Genome Sequencing to Bolster Precision Medicine

Zombie Unicorns are Haunting Silicon Valley

Immune Cells Drive Alzheimer's Disease

Gene Wilder's Fight to Change Screening for Ovarian Cancer

Stopgap Pauses Changes to Federal Science Grant Process

"Revolution Medicines" Develops Groundbreaking Pancreatic Cencer Treatment

Dr. Peter Embí to lead NIH’s National Library of Medicine

$ 37M Investment in Aging Research

Find more news & resources on our LinkedIn page

Bridging science, innovation & capital

COMPANY

SUPPORT

CONNECT

Privacy Policy

Cookies

Terms & Conditions

About us

Contact us

Instagram

Bluesky

LinkedIn